By Colin Kellaher
Clinical-stage biotechnology company Allakos, which early this year pulled the plug on its lead program and slashed its workforce by 75%, has struck a deal to be acquired for about $30 million.
Allakos on Wednesday said Concentra Biosciences, controlled by life sciences-focused investment firm Tang Capital, has agreed to pay 33 cents a share in cash for the Menlo Park, Calif., company, a 52% premium to Tuesday's closing price of 21.7 cents.
The deal is slated to close in May.
Allakos shares collapsed in late January after the company said it was ending further development of AK006, its most advanced product candidate, following the failure of the drug in a phase 1 study in the skin condition chronic spontaneous urticaria.
Trading in shares of Allakos was halted premarket on Wednesday. The stock traded as low as 21.6 cents during Tuesday's session, its lowest level since the company went public in 2018.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 02, 2025 08:35 ET (12:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。